Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)

Purpose This study investigated the safety and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) re-administration after recovery from EGFR-TKI-induced interstitial lung disease (ILD). Methods This multicenter retrospective study collected data from consecutive adva...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung 2024-02, Vol.202 (1), p.63-72
Hauptverfasser:	Kanaji, Nobuhiro, Ichihara, Eiki, Tanaka, Takaaki, Ninomiya, Takashi, Kozuki, Toshiyuki, Ishikawa, Nobuhisa, Nishii, Kazuya, Shoda, Hiroyasu, Yamaguchi, Kakuhiro, Kawakado, Keita, Toyoda, Yuko, Inoue, Masaaki, Miyatake, Nobuyuki, Watanabe, Naoki, Inoue, Takuya, Mizoguchi, Hitoshi, Komori, Yuta, Kojima, Kazuki, Kadowaki, Norimitsu
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides adrenal cortex hormones Aniline Compounds Antineoplastic Agents - adverse effects Effectiveness Enzyme inhibitors Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - genetics ErbB Receptors - therapeutic use Erlotinib Hydrochloride - adverse effects Gefitinib Gefitinib - adverse effects Growth factors Humans Indoles Interstitial Lung Disease Kinases Lung Lung diseases Lung Diseases, Interstitial - chemically induced Lung Diseases, Interstitial - drug therapy Lung Neoplasms lungs Medical prognosis Medicine Medicine & Public Health Mutation Non-small cell lung carcinoma patients Pneumology/Respiratory System prognosis Protein Kinase Inhibitors - adverse effects Pyrimidines Quinazolines - adverse effects Receptors respiratory tract diseases Retrospective Studies Safety Survival Time use Tyrosine Tyrosine Kinase Inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!